Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2021-10-28 M&A Activity
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
XVIVO har ingått avtal om att förvärva det amerikanska företaget för organhämtning, Star Teams, och finansierar förvärvet genom en nyemission av aktier
M&A Activity Classification · 95% confidence The document is a press release from XVIVO Perfusion AB announcing the acquisition of 'Star Teams' and the associated financing through a directed share issue. It details the acquisition terms, the strategic rationale, and the financial background of the target company. While it mentions a future conference call, the document itself is a primary announcement of a corporate transaction (M&A) and the related capital raising activity. According to the filing definitions, documents related to merger proposals or takeover bids are classified as TAR (M&A Activity).
2021-10-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – september 2021' (Interim Report January – September 2021) for XVIVO Perfusion AB. It contains comprehensive financial statements, including income statements, balance sheet data, and management commentary on business performance for the third quarter and the nine-month period. It is clearly a quarterly/interim financial report, not an announcement or a summary. 9M 2021
2021-10-21 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January – September 2021' and contains comprehensive financial statements, key ratios, and management commentary for the specified period. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-10-21 English
Language correction: XVIVO Capital Markets Day presents strategic focus areas for 2022-2026
Report Publication Announcement Classification · 99% confidence The document is a press release announcing the company's 'Capital Markets Day' event, where senior executives will present strategic focus areas for 2022-2026, financial targets (EBIT/EBITDA margins), and future plans. It explicitly mentions the event date (September 23, 2021) and provides a link to the live broadcast and a recording. Crucially, it includes an attachment titled 'Language correction: XVIVO Capital Markets Day presents strategic focus areas for 2022-2026' which is likely the presentation material itself. Since the primary content is an announcement about an investor event where strategy and financial outlook are detailed, this strongly aligns with an Investor Presentation (IP). Although it is a press release format, the core subject matter is the presentation content being shared with the market, making IP a better fit than a general Regulatory Filing (RNS) or Earnings Release (ER). The document length is relatively short (3680 chars), suggesting it is an announcement *about* the presentation rather than the full presentation itself, but the content is clearly focused on investor-facing strategic material.
2021-09-23 English
XVIVO presenterar strategiska fokusområden för 2022-2026 på kapitalmarknadsdagen
Regulatory Filings Classification · 90% confidence The document is a press release announcing a Capital Markets Day event. It outlines the strategic focus areas for 2022-2026 and mentions that the event will be broadcast live. While it contains strategic information, it is an announcement of an investor event rather than the full investor presentation deck itself. According to the 'Menu vs Meal' rule, announcements of events or reports are classified as Regulatory Filings (RNS) when they do not fit other specific categories like RPA (which is for report publication).
2021-09-23 Swedish
XVIVO Capital Markets Day presents strategic focus areas for 2022-2026
Investor Presentation Classification · 99% confidence The document text explicitly describes an event titled "XVIVO Capital Markets Day" where the CEO and senior executives present strategic focus areas, financial targets, and actions for the period 2022-2026. This content—a presentation detailing strategy and financial outlook for investors—is characteristic of an Investor Presentation (IP). Although it mentions the event is broadcast live, the core content being communicated is the presentation material itself, not just an announcement of a report (which would suggest RPA or RNS). The length (3340 chars) is substantial enough to contain presentation details rather than just a brief notice. Therefore, 'IP' is the most appropriate classification.
2021-09-23 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.